Cargando…
Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) survivors experience high rates of adverse health sequelae and increased mortality over long-term follow-up. We conducted this multicenter cohort study to evaluate long-term mortality and causes of death in iTTP survivors. Between 2003 and 2...
Autores principales: | Sukumar, Senthil, Brodsky, Max, Hussain, Sarah, Yanek, Lisa, Moliterno, Alison, Brodsky, Robert, Cataland, Spero R., Chaturvedi, Shruti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864652/ https://www.ncbi.nlm.nih.gov/pubmed/34461629 http://dx.doi.org/10.1182/bloodadvances.2020004169 |
Ejemplares similares
-
Cardiovascular Disease and Stroke in Immune TTP–Challenges and Opportunities
por: Sukumar, Senthil, et al.
Publicado: (2023) -
SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura
por: Shah, Hridaya, et al.
Publicado: (2022) -
A complementary new drug for PNH
por: Brodsky, Robert A.
Publicado: (2020) -
Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination
por: Deucher, William, et al.
Publicado: (2022) -
Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management
por: Sukumar, Senthil, et al.
Publicado: (2021)